bipuvacain
PreclinicalSmall molecule
bipuvacain is one of 32 small molecule programs targeting Abortion. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Abortion
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Mifeprex
DDanco
Approved
Amidate
PfizerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Duragesic
CCephalon
Approved
Prometrium
FerringApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Pitocin
RRetrophin
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bipuvacain. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKristina Gemzell Danielsson